Health Market Access — Explained
Practical guidance on NMPA registration, FDA compliance, Blue-hat certification, and cross-border health market entry — from specialists who've been inside the regulatory system.
NMPA Medical Device Registration: Complete Guide for Foreign Manufacturers (2026)
Step-by-step guide to registering a medical device with China's NMPA — Class I, II, and III pathways, realistic timelines, government fees, Authorized Agent requirements, and the most common reasons dossiers fail. Written by former NMPA review specialists.
Class I–III
China Medical Device Standards & Classification: A Practical Guide for Foreign Manufacturers (2025)
How China's mandatory standards, classification catalogue, and drug-device combination rules work in practice — plus what the upcoming Medical Device Management Law changes for your dossier.
China's Medical Device Regulatory Internationalization: IMDRF, eRPS & Essential Principles Explained (2025)
How China's 国办发[2024]53号 policy is accelerating NMPA alignment with IMDRF — covering eRPS, Essential Principles, UDI rollout, MRCT, and what 90%+ international standards adoption means for your registration.
China's Brain-Computer Interface Medical Device Regulations: A Complete Guide for 2026
How China's NMPA classifies BCI devices — from Class II wearables to Class III invasive implants — with timelines, fast-track pathways, and what foreign manufacturers need to know.
China Medical Device Regulatory Landscape 2025: Industry Overview & Reform Roadmap
A comprehensive look at China's ¥1.35T medical device market — the 3-tier classification system, regulatory hierarchy, and major reforms including conditional approval, real-world evidence, and overseas clinical data recognition.
China Cardiovascular Implantable Device Market & NMPA Registration: A Complete Overview
The ¥50B cardiovascular implant market, 380+ valid NMPA certificates, and what Class III registration really requires — EP checklist, technical standards, clinical evaluation pathways, and on-site technical review.
China Cardiovascular Device Technical Standards & Clinical Evaluation: An NMPA Submission Guide
Practical walkthrough of NMPA's EP Checklist framework, mandatory standards by device category (stents, valves, grafts, occluders), and the three clinical evaluation pathways — including when overseas trial data can replace a China trial.
China Tumor Genetic Testing IVD: NMPA Registration, NGS Approvals & LDT Pilot (2025)
Complete guide to NMPA registration for tumor genetic testing IVDs — 29 NGS kits, 85 PCR CDx, and 37 methylation products approved; three clinical evaluation pathways; CDx co-development rules; and the LDT pilot program for hospitals.
China's Three-Healthcare Coordination Policy: Medical Device Implications — UDI, VBP & Clinical Urgent Import (2025)
How 国办发[2024]53号 reshapes device market access — clinical urgent import for unregistered overseas devices, UDI phase rollout, VBP quality oversight, insurance coding alignment, and what innovative manufacturers need to know.
China Medical Device Innovation Policy 2026: Priority Review, AI Registration Reform & the 10 NMPA Measures
NMPA's 10 reform measures under 53号文 — priority review for BNCT, implantable BCI, ultra-high-field MRI, transcatheter tricuspid valve and ECMO; clinical trial protocol pre-review; and four new AI device registration rules.
China Medical Device Commercialization: Crossing the Valley of Death with TRL Assessment & NMPA's EP Checklist
Why medical device innovations fail to reach China's market — the Valley of Death explained, TRL readiness levels for NMPA registration, EP Checklist conformity structure, and on-site technical review requirements.